公开(公告)号：US20080299114A1

公开(公告)日：2008-12-04

申请号：US12049233

申请日：2008-03-14

申请人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

发明人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

IPC分类号： A61K39/395 ,  C07K16/00 ,  A61P11/00 ,  A61P33/00 ,  A61P31/12

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/461 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/92

摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。

公开(公告)号：US20110318337A1

公开(公告)日：2011-12-29

申请号：US13115810

申请日：2011-05-25

申请人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

发明人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

IPC分类号： A61K39/395 ,  A61P11/00 ,  A61P29/00

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/461 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/92

摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。

公开(公告)号：US07964705B2

公开(公告)日：2011-06-21

申请号：US12049233

申请日：2008-03-14

申请人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

发明人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

IPC分类号： C12P21/08

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/461 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/92

摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。